March 28, 2012
IntelliCell (OTC QB:SVFC) Updating: FDA Warning Letter
March 12, 2012
Aastrom Biosciences (ASTM), Q4/11 and FY11 Results
March 10, 2012
A Welcome Financing Endorsement from Tim Mayleben, CEO of Aastrom (ASTM)
March 9, 2012
Aastrom Biosciences (ASTM) Completes $40m Financing
March 8, 2012
Cytori (CYTX) FY11 Achievements and Highlights
February 7, 2012
Cytori (CYTX) A Daily Perspective, Sellers beget Buyers
February 1, 2012
Athersys (ATHX) Positive Results of MultiStem(R) Clinical Trial
January 23, 2012
Verastem plans IPO this week
December 7, 2011
RegMed Daily, Mid-Day, 12/7/11, pessimism returns distracting markets
November 8, 2011
Aastrom Biosciences (ASTM) Q3/11 Results
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.